Skip to main content

Table 2 Unadjusted efficacy estimates relative to treatment with entecavir

From: The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis

 

Fixed effects model

Entecavir 0.5 mg

1.00 (Baseline)

Adefovir 10 mg

0.64 (0.42, 0.87)

Lamivudine 100 mg

0.54 (0.46, 0.63)

Placebo

0.10 (0.04, 0.19)

Telbivudine 600 mg

0.88 (0.76, 1.00)

Tenofovir 245 mg

1.43 (1.30, 1.54)

Interferon alfa

0.21 (0.09, 0.38)

Peginterferon alfa-2a/2b

0.34 (0.23, 0.46)

  1. Results are shown as relative risk (95% credible interval). A relative risk <1 should be interpreted as a given treatment being less efficacious (that is, worse) than entecavir, and a value >1 being more efficacious (that is, better).
Back to article page

Systematic Reviews

ISSN: 2046-4053